PE20060769A1 - Composiciones farmaceuticas que comprenden una sal de un analogo de somatostatina - Google Patents

Composiciones farmaceuticas que comprenden una sal de un analogo de somatostatina

Info

Publication number
PE20060769A1
PE20060769A1 PE2005001479A PE2005001479A PE20060769A1 PE 20060769 A1 PE20060769 A1 PE 20060769A1 PE 2005001479 A PE2005001479 A PE 2005001479A PE 2005001479 A PE2005001479 A PE 2005001479A PE 20060769 A1 PE20060769 A1 PE 20060769A1
Authority
PE
Peru
Prior art keywords
salt
mono
pharmaceutical compositions
compositions including
somatostatin analogue
Prior art date
Application number
PE2005001479A
Other languages
English (en)
Inventor
Olivier Lambert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20060769A1 publication Critical patent/PE20060769A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA PARA ADMINISTRACION PARENTERAL, QUE COMPRENDE UNA SAL DE MONO- O DI- ASPARTATO, MONO- O DI- GLUTAMATO, MONO- O DI- SUCCINATO, ACETATO O CITRATO DE UN ANALOGO DE SOMATOSTATINA Y AGUA. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION. DICHA COMPOSICION PRESENTA UN pH DE ENTRE 3 Y 7, Y FORMA UN SISTEMA DE DEPOSITO GELEIFICANTE DESPUES DE SU INYECCION AL ENTRAR EN CONTACTO CON CON EL FLUIDO CORPORAL. ESTA COMBINACION ES UTIL PARA EL TRATAMIENTO DE TRASTORNOS QUE ESTEN RELACIONADOS CON UN EXCESO DE SECRECION DE GH Y/O CON UN EXCESO DE IGF-1, TRATAMIENTO DE LA ANGIOGENESIS, ENTRE OTROS
PE2005001479A 2004-12-22 2005-12-16 Composiciones farmaceuticas que comprenden una sal de un analogo de somatostatina PE20060769A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0428151.5A GB0428151D0 (en) 2004-12-22 2004-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
PE20060769A1 true PE20060769A1 (es) 2006-09-28

Family

ID=34113101

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001479A PE20060769A1 (es) 2004-12-22 2005-12-16 Composiciones farmaceuticas que comprenden una sal de un analogo de somatostatina

Country Status (19)

Country Link
US (2) US20100029550A1 (es)
EP (1) EP1830806B1 (es)
JP (1) JP4977622B2 (es)
KR (1) KR101335757B1 (es)
CN (1) CN101072551B (es)
AR (1) AR051803A1 (es)
AU (1) AU2005318454B2 (es)
BR (1) BRPI0519209A2 (es)
CA (1) CA2585116C (es)
ES (1) ES2515097T3 (es)
GB (1) GB0428151D0 (es)
GT (1) GT200500358A (es)
MX (1) MX2007007572A (es)
PE (1) PE20060769A1 (es)
PL (1) PL1830806T3 (es)
PT (1) PT1830806E (es)
RU (1) RU2395274C2 (es)
TW (1) TW200637612A (es)
WO (1) WO2006066868A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
CA2702940C (en) 2007-12-03 2016-09-13 Andrea Vitali New non-selective somatostatin analogues
EA023128B1 (ru) 2010-01-13 2016-04-29 Ипсен Фарма С.А.С. Способ получения инъекционной фармацевтической композиции с замедленным высвобождением ланреотида
US8535544B2 (en) 2010-07-26 2013-09-17 International Business Machines Corporation Structure and method to form nanopore
WO2013131879A1 (en) 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
US11278507B2 (en) 2016-09-06 2022-03-22 Monell Chemical Senses Center Method of regulating immunity in the intestines
AU2018230429B2 (en) * 2017-03-09 2023-06-15 Corcept Therapeutics, Inc. Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
AU2022390573A1 (en) * 2021-11-22 2024-05-16 SpecGx LLC Injectable sustained release pharmaceutical composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE14226T1 (de) * 1981-12-24 1985-07-15 Ciba Geigy Ag Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung.
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
ATE318580T1 (de) 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
JP2005525374A (ja) * 2002-03-04 2005-08-25 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 担体ペプチドを含有する持続放出ドラッグ製剤
GB0300095D0 (en) 2003-01-03 2003-02-05 Novartis Ag Organic compounds
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
ES2399651T3 (es) * 2008-07-08 2013-04-02 Novartis Ag Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena

Also Published As

Publication number Publication date
EP1830806A2 (en) 2007-09-12
PT1830806E (pt) 2014-11-24
CA2585116C (en) 2014-05-20
JP2008524290A (ja) 2008-07-10
GT200500358A (es) 2006-08-07
WO2006066868A2 (en) 2006-06-29
GB0428151D0 (en) 2005-01-26
AR051803A1 (es) 2007-02-07
US9303067B2 (en) 2016-04-05
PL1830806T3 (pl) 2015-03-31
TW200637612A (en) 2006-11-01
ES2515097T3 (es) 2014-10-29
KR101335757B1 (ko) 2013-12-02
AU2005318454B2 (en) 2009-08-20
MX2007007572A (es) 2007-07-24
CA2585116A1 (en) 2006-06-29
US20100029550A1 (en) 2010-02-04
BRPI0519209A2 (pt) 2009-01-06
AU2005318454A1 (en) 2006-06-29
EP1830806B1 (en) 2014-09-03
CN101072551B (zh) 2013-04-24
RU2007128101A (ru) 2009-01-27
WO2006066868A3 (en) 2006-10-12
US20150038414A1 (en) 2015-02-05
JP4977622B2 (ja) 2012-07-18
CN101072551A (zh) 2007-11-14
RU2395274C2 (ru) 2010-07-27
KR20070090942A (ko) 2007-09-06

Similar Documents

Publication Publication Date Title
PE20060769A1 (es) Composiciones farmaceuticas que comprenden una sal de un analogo de somatostatina
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
HRP20171217T1 (hr) Stabilni pripravak koji sadrži pthrp i njegova upotreba
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
PE20130578A1 (es) Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa
ES2531215T3 (es) Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
ATE541582T1 (de) Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
EP1504778A3 (en) Implantable pump for the treatment of obesity
PE20030575A1 (es) Soluciones de meloxicam estables y muy concentradas para la inyeccion sin aguja
MX338338B (es) Composiciones y metodos utiles para el tratamiento de enfermedades respiratorias.
ES2531083T3 (es) Formulaciones estables de polipéptidos y usos de las mismas
YU8803A (sh) Tečni oblik metformina
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
RS53127B (en) STABLE PROTEIN FORMULATIONS
NZ623123A (en) A process for concentration of a polypeptide
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
RS54543B1 (en) Fast acting gastric acid secretion inhibitor
NI200600146A (es) Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso
ECSP066477A (es) Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo
PE20230819A1 (es) Composiciones y usos de glp-1
HUP0202749A2 (hu) Levoszimendánt tartalmazó oldat formájú gyógyszerkészítmény
ATE507818T1 (de) Orale verabreichung eines calcitonins
MXPA02011389A (es) Forma de administracion farmaceutica para peptidos, procedimiento para su preparacion y aplicacion.
NZ560648A (en) Formulation for aviptadil (vasoactive intestinal peptide, VIP)
WO2006095363A3 (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
FC Refusal